Pluvicto – Talk Bio

Actionable Insights Powered by AI

Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto

9 months ago talkbio0Tagged Congress (U.S. Legislature), ESMO, Lantheus, Phase 3 SPLASH, Pluvicto, PSMA, PSMA-positive metastatic castration-resistant prostate cancer

Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto

Expansion of Pluvicto Use Sought by Novartis Following Positive Prostate Cancer Study Update

1 year ago talkbio0Tagged Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, Novartis, Pluvicto, Progression-Free Survival, PSMAfore trial, Radiographic, rPFS

Novartis, Pluvicto, Broader use, Prostate cancer, PSMAfore trial, Radiographic progression-free survival (rPFS), Metastatic castration-resistant prostate cancer (mCRPC)